| Previous Close | 80.98 |
| Open | 80.81 |
| Bid | 62.13 x 100 |
| Ask | 89.95 x 100 |
| Day's Range | 80.76 - 81.62 |
| 52 Week Range | 78.42 - 102.06 |
| Volume | 1,117,228 |
| Avg. Volume | 1,304,498 |
| Market Cap | 14.18B |
| Beta | 1.94 |
| PE Ratio (TTM) | -24.10 |
| EPS (TTM) | -3.36 |
| Earnings Date | Oct 25, 2017 - Oct 30, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 112.47 |
- TheStreet.com•2 days ago
Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst
Evercore ISI analyst Josh Schimmer is bullish on biotech.
- Motley Fool•4 days ago
Why Gilead Sciences Might Not Make an Oncology Acquisition
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
- PR Newswire•4 days ago
BioMarin to Attend Upcoming Investor Conferences
- Citi's 12th Annual Biotech Conference on September 6 in Boston - Baird's 2017 Global Healthcare Conference on September 7 in New York - Morgan Stanley 15th Annual Global Healthcare Conference on September ...
